| Literature DB >> 30034664 |
Ladan Goshayeshi1,2, Ali Bahari1,2, Farnaz Torabian3, Kasra Molooghi4, Ermia Musavi Mohammadi4, Mehrdad Sahranavard5, Hoda Hosseinzadeh Maleki6, Zahra Sabzeh Noughabi7, Benyamin Hoseini8.
Abstract
BACKGROUND: Early detection of atherosclerosis is an essential means of decreasing cardiovascular events and its associated mortality. Systemic inflammatory diseases such as ulcerative colitis (UC), are thought to be a contributing factor to atherosclerosis due to the rise of inflammatory cytokines.Entities:
Keywords: Atherosclerosis; Cardiovascular disease; Carotid intima-media thickness; Inflammatory bowel disease; Ulcerative colitis
Year: 2018 PMID: 30034664 PMCID: PMC6049966 DOI: 10.19082/6956
Source DB: PubMed Journal: Electron Physician ISSN: 2008-5842
The c-IMT finding of patients with UC and Non-UC in included studies
| Ref. no. | Sample size | UC | Non-UC (n) | c-IMT | Mean difference | p-value | STROBE score | Comments | |
|---|---|---|---|---|---|---|---|---|---|
| UC | Non-UC | ||||||||
| 50 | 19 | 31 | 0.55±0.1 | 0.51±0.06 | 0.04±0.04 | 0.14 | 28 | c-IMT was not significantly higher in patients with UC | |
| 67 | 37 | 30 | 0.86±0.15 | 0.55±0.29 | 0.31±0.14 | <0.001 | 30 | c-IMT was significantly higher in patients with UC | |
| 58 | 16 | 42 | 0.61±0.06 | 0.52±0.06 | 0.09±0.0 | <0.0005 | 29 | c-IMT was significantly higher in the UC patients than in the non-UCs | |
| 120 | 60 | 60 | 0.68±0.07 | 0.52±0.04 | 0.16±0.03 | 0.001 | 33 | c-IMT was significantly higher in the UC patients than in the non-UC | |
| 140 | 74 | 66 | 0.44±0.8 | 0.41±0.08 | 0.03±0.0 | 0.152 | 29 | c-IMT was not significantly higher in patients with UC | |
UC: Ulcerative Colitis;
c-IMT: carotid intima-media thickness;
Sample size: patients with the diagnosis of Ulcerative Colitis are analyzed separately from IBD patients in this table, but the number of non-UC patients were initially selected according to the sum of IBD patients in the original article. Total sample size: 435, Total UC: 206, Total non-UC group: 229
Figure 1Flow diagram for study selection.
Demographic, ultrasonography and drug history data of patients with UC and non-UC in included studies.
| Ref. no. | Drugs* | Disease duration (years)* | Age (years) | M/F | BMI (kg/m2) | Smoking | cfPWV (m/s) | FMD (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UC | Non-UC | UC | Non-UC | UC | Non-UC | UC | Non-UC | UC | Non-UC | UC | Non-UC | |||
| N/A | N/A | 36.4±8.9 | 32.7±6.9 | 10/9 | 16/15 | N/A | N/A | 1 | 9 | N/A | N/A | 10.±5.4 | 18.7±9.2 | |
| Aminosalicylates, Corticosteroid or immunosuppressive, Infliximab | N/A | 48±15 | 45±8 | 21/16 | 9/21 | 27.0±4.4 | 27.5±4.1 | 6 | 4 | 8.94±2.98 | 7.17±1.73 | N/A | N/A | |
| 5-ASA, Azathioprine, Anti-TNF-a, Corticosteroids | 6.5 | 33.9±11.4 | 36.3±10.7 | 7/9 | 20/22 | 24.4±6 | 23.2±4.2 | 1 | 22 | N/A | N/A | N/A | N/A | |
| Mesalamine, azathioprine | 7.24±2.05 | 35.6±6.2 | 34.9±5.2 | 33/27 | 32/28 | 20.4±1.5 | 21.0±1.7 | N/A | N/A | N/A | N/A | N/A | N/A | |
| Mesalazine, Steroid, Azathiopurine, Anti-TNF | 4.1±3.9 | 32.9±8.4 | 30.9±7 | 54/20 | 45/21 | 24.2±3.8 | 23.6±2.8 | 1 | 2 | 8.13±1.61 | 6.85±0.95 | 9.6±5.1 | 15.1±9.7 | |
M/F, Male/Female; BMI, Body Mass Index; cf-PWV, carotid–femoral Pulse Wave Velocity; FMD, Flow-Mediated Dilation; N/A, Not available.
Biochemical and inflammatory data of patients with UC and non-UC in included studies.
| Ref. no. | ESR (mm/h) | CRP (mg/dL) | HDL-c (mg/dL) | LDL-c (mg/dL) | TG (mg/dL) | FBS (mg/dL) | HOMA.IR | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UC | Non-UC | UC | Non-UC | UC | Non-UC | UC | Non-UC | UC | Non-UC | UC | Non-UC | UC | Non-UC | |
| 21.1 ±11.3 | 8.4 ±5.2 | 6.7 ±5.7 | 1.55 ±1.89 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| 22.4 ±18.4 | 13.5 ±7.3 | 0.83 ±1.19 | 0.34 ±0.24 | 45 ±11 | 45 ±9 | 135 ±39 | 126 ±36 | 135 ±66 | 135 ±83 | 104 ±18 | 102 ±16 | N/A | N/A | |
| N/A | N/A | 3.2 (0.1–36.2) | 1.04 (0.9–1.21) | 53 ±12 | 49 ±11 | 114 ±36 | 125 ±32 | 90 ±46 | 98.3 ±49.7 | N/A | N/A | N/A | N/A | |
| 41.06 ±15.76 | 15.14 ±4.54 | N/A | N/A | 40.2 ±5.4 | 40.2 ±5.4 | 79.6 ±10.0 | 79.3 ±10.8 | 87.7 ±9.7 | 87.7 ±8.8 | 94.1 ±6.6 | 90.4 ±7.0 | 2.94 ±0.99 | 1.56 ±0.20 | |
| 23.7 ±22.6 | 9.6 ±8 | 10.2 ±19.7 | 3.1 ±3.7 | 46.7 ±12.0 | 50.3 ±15.4 | 103.9 ±32.4 | 103.6 ±28.2 | 117.1 ±51.9 | 123.3 ±73.3 | N/A | N/A | N/A | N/A | |
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; HDL-c, high density lipoprotein; LDL, low density lipoprotein; TG, triglyceride; FBS, fasting blood glucose; HOMA.IR, Homeostasis model assessment of insulin resistance; N/A, Not available.
Figure 2Forest plot of the included studies assessing the association between c-IMT and UC; a diamond data marker represents the overall mean difference estimate, 95 % CI and Relative weight for the outcome of interest.
Figure 3Funnel plot of the included studies represents the t-value =0.31 and p-value (2-tailed) =0.77 in Egger’s regression test that indicate publication bias did not exist for the UC.